The US Food and Drug Administration recommends screening for the HLA-B*1502 allele before initiation of carbamazepine therapy in patients of Asian ancestry, but there remains unclear evidence of a relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) among carbamazepine users, especially in some racial/ethnic populations.
S tevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions affecting the skin and mucous membranes. 1 Both SJS and TEN are characterized by blisters arising on purple macules. Lesions are widespread and usually predominate on the trunk of the body. The percentage of skin detachment body surface area differentiates SJS and TEN. 2 Although the incidence of SJS and TEN is low (0.4-6 cases per million persons per year), 1, 3 mortality rates are as high as 5% to 12.5% for SJS, 33.3% for SJS and TEN overlap, and 30% for TEN. 1, 4 The primary identifiable causative agent of SJS and TEN is medication use (almost 80% of cases). 1 Other factors implicated include chemicals, viral infection, immunizations, and mycoplasma pneumonia. Several classes of medication have been strongly associated with SJS and TEN, including antibiotics, antiepileptic drugs, and xanthine oxidase inhibitors. 1 Carbamazepine is the most common cause of SJS or TEN. 5, 6 A European study 7 found that the risks of SJS or TEN among carbamazepine and phenytoin users were more than 90 and 53 times greater than those of nonusers, respectively. Multiple investigators have reported a relationship between HLA genes and SJS and TEN induced by carbamazepine. Specifically, the HLA-B*1502 allele (OMIM 142830.0002) has been associated with carbamazepine-induced SJS and TEN. [8] [9] [10] [11] In addition to carbamazepine, allopurinol can be a causative agent of SJS and TEN, particularly among those carrying the HLA-B*5801 allele. 12 Based on these observational studies, the US Food and Drug Administration published an alert to health care professionals that severe allergic skin reactions can be caused by carbamazepine use in patients with the HLA-B*1502 allele and recommended screening for the allele before initiation of carbamazepine therapy in patients of Asian ancestry. 13 Despite the alert from the US Food and Drug Administration, some studies 9, 11, [14] [15] [16] have demonstrated no such association in the Japanese population. This difference likely reflects race/ethnicity variation, as well as nonreporting of less severe cutaneous drug reactions. 9, 11, [14] [15] [16] To fully understand the relationship between HLA-B*1502 and SJS and TEN among carbamazepine users, a systematic review identifying all studies assessing such association is needed. A transparent and reproducible process may be provided using a systematic review approach. This method can elucidate potential similarities and differences that may explain the findings. Therefore, this study was undertaken to systematically review all relevant studies and to quantitatively synthesize the magnitude of the relationship between the HLA-B*1502 allele and carbamazepine-induced SJS and TEN.
Methods

Data Sources and Search Strategy
We searched EMBASE, PubMed, clinicaltrials.gov, The Cochrane Library, IPA (International Pharmaceutical Abstracts), HuGENet (Human Genome Epidemiology Network), and CINAHL (Cumulative Index to Nursing and Allied Health Literature). All databases were searched from their inception until January 8, 2013. Searches were performed using keywords and synonyms for HLA-B and carbamazepine and relevant terms for SJS and TEN. For PubMed and The Cochrane Library, Medical Subject Headings were searched for HLA-B and carbamazepine and for SJS and TEN. There was no language or study design restriction, but only human studies were included. Additional studies were retrieved from the reference lists of the selected articles.
Study Selection
Two reviewers (W. Tangamornsuksan and R.S.) independently assessed abstracts and titles retrieved from the comprehensive searches for study inclusion. The inclusion criteria were studies that (1) investigated the relationship between HLA-B*1502 and carbamazepine-induced SJS and TEN and (2) reported sufficient data for calculating the frequency of HLA-B*1502 carriers among cases and controls. Any disagreements were discussed until consensus between the 2 reviewers could be reached.
Data Extraction and Quality Assessment
All articles were extracted independently by the reviewers; discrepancies were resolved by discussion. The following data were extracted from each study: study design, eligibility criteria, diagnostic criteria, patient demographics, genotype distribution, HLA-B genotyping technique, selection of cases and controls, dosage of carbamazepine and duration of use, and results of Hardy-Weinberg equilibrium (a state of equilibrium under the mendelian law of genetic inheritance) in the control group.
Hardy-Weinberg equilibrium was tested to check if the included individuals were in equilibrium for the frequencies of genotypes. 17, 18 Equilibrium implies that the included individuals are likely representative of the population. 19, 20 We used the Newcastle-Ottawa Scale 21 to assess the quality of the studies included in the review. This scale is an 8-item instrument, categorized into the following 3 domains: selection of participants, comparability between 2 groups, and the assessment of exposures and outcomes. A system of stars is used to provide quality ratings for studies.
Data Analysis
The overall odds ratios (ORs) with corresponding 95% CIs were calculated to determine the relationship between the presence of HLA-B*1502 in at least 1 allele and carbamazepineinduced SJS and TEN. All analyses were performed with the method by DerSimonian and Laird 22 using a random-effects model. The analyses were also performed separately on studies using different types of control groups (eg, control subjects obtained from the study [matched control study] or control subjects obtained from the population database [population study]). The primary outcome measure was analyzed using the matched control study. Subgroup analyses by race/ethnicity were also performed to determine the robustness of the findings. Statistical heterogeneity was assessed via the Q statistic and I 2 tests. 23 P ≤ .10 indicated heterogeneity between studies. I 2 values of 25% and 50% denoted low heterogeneity and moderate heterogeneity, respectively, across studies. 24 Funnel plot, Begg test, and Egger test were used to evaluate publication bias.
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Results
Study Selection
In total, 525 articles were identified by the search. Sixteen articles 14, 16, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] met the inclusion criteria. Some SJS and TEN cases included in the studies by Chung et al, 9 Ikeda et al, 15 Wang et al, 41 and Kulkantrakorn et al 42 were also in the studies by Hung et al, 28 Kaniwa et al, 29 Shi et al, 36 and Tassaneeyakul et al, 37 respectively. In addition, 1 study 43 and 2 abstracts 44,45 potentially met the inclusion criteria but lacked key information. Of the original 525 articles, 16 remaining studies were included in the meta-analysis ( Figure 1) . No additional articles were identified via a review of the bibliographies of the included studies.
Study Characteristics
Characteristics of the included studies are summarized in Table 1 . The studies included 227 SJS or TEN cases 14, 16, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] ; in addition, there were 602 matched control subjects 14, 28, [30] [31] [32] [35] [36] [37] [38] [39] [40] and 2949 population control subjects. 16 
Quality Assessment
The methodological quality of all studies was summarized as a mean Newcastle-Ottawa Scale score of 5 (range, 4-6; maximum score, 9). These results are given in Table 1 .
Quantitative Synthesis Analysis Using Matched Control Studies
Eleven studies 16, 27, [30] [31] [32] [33] [34] [36] [37] [38] 40 were included in a comparison of the HLA-B*1502 carrier frequencies in the cases and carbamazepine-tolerant controls. There were 175 SJS or TEN cases These observed racial/ethnic differences could be explained by the fact that HLA-B*1502 may not be the only gene associated with SJS and TEN in patients using carbamazepine. For example, another HLA allele (HLA-A*3101) is related to SJS and TEN; the ORs for carriers of this gene using carbamazepine are approximately 26-fold higher for Europeans 48 and 11-fold higher for Japanese. 49 Furthermore,
Hung et al 28 reported that HLA-A*3101 was associated with carbamazepine-induced maculopapular eruptions (OR, 17.5; 95% CI, 4.6-66.5) and hypersensitivity syndrome (OR, 7.1; 95% CI, 3.1-16.5) in a Han-Chinese population. Similar to the observed relationship between HLA-B*1502 and SJS and TEN among carbamazepine users, there are some examples of associations in which more than 1 gene has a major role.
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Although the mechanism by which HLA-B*1502 contributes to SJS and TEN among carbamazepine users is not fully understood, it is well recognized that HLA-B molecules supply endogenous or processed exogenous antigens to T cells, eliciting an adaptive immune response. It seems that a specific HLA allele is required for the activation of drug-specific T cells by the culprit drug. The T-cell receptor of the effector T cell is thought to recognize the drug-peptide complex bound by the specific HLA-B molecule on the antigenpresenting cell, resulting in the release of immune mediators and leading to robust adaptive immune reactions in severe cutaneous reactions.
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Our systematic meta-analysis has several limitations. First, this study focused only on the relationship between the HLA-B*1502 allele and carbamazepine-induced SJS and TEN. Other genes that may be associated with SJS and TEN (such as HLA-A*3101) were excluded from our study. Second, an article 43 and 2 abstracts 44,45 that potentially met our study criteria were not included in the meta-analysis because they did not provide the number of control patients, which was important information for the analysis. On the one hand, we do not have long-term follow-up of Johnson's initial patient, and, as with many n-of-1 clinical trials, we lack adequate data on safety and efficacy on which to base further recommendations. Interest in alternative interventions for severe acne waned greatly with the success of systemic retinoids. Furthermore, use of topical bovine excrement would certainly test the limits of acceptability for today's discerning patients, even with a marketing strategy that touts its natural origins.
On the other hand, medicinal formulations of equine urine, porcine digestive hormones, bovine bile, and other below-the-diaphragm excretions are regularly used in medicine and generally accepted by the wider public. Human feces, in the form of an allogeneic transplant, is now an accepted treatment for Clostridium difficile enteritis. 2 Evidence of the microbiome's role in healthy and diseased skin, and its potential manipulation in therapy, is piling up. Kang et al 3 have shown that some human fecal enterococci have in vitro activity against Proprionobacterium acnes, which suggests further exploration of fecotherapy in dermatology.
